The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A three-dimensional human neural cell culture model of Alzheimer’s disease
Open accessAbstract
Alzheimer's disease is the most common form of dementia, characterized by two pathological hallmarks: amyloid-β plaques and neurofibrillary tangles. The amyloid hypothesis of Alzheimer's disease posits that the excessive accumulation of amyloid-β peptide leads to neurofibrillary tangles composed of aggregated hyperphosphorylated tau. However, to date, no single disease model has serially linked these two pathological events using human neuronal cells. Mouse models with familial Alzheimer's disease (FAD) mutations exhibit amyloid-β-induced synaptic and memory deficits but they do not fully recapitulate other key pathological events of Alzheimer's disease, including distinct neurofibrillary tangle pathology. Human neurons derived from Alzheimer's disease patients have shown elevated levels of toxic amyloid-β species and phosphorylated tau but did not demonstrate amyloid-β plaques or neurofibrillary tangles. Here we report that FAD mutations in β-amyloid precursor protein and presenilin 1 are able to induce robust extracellular deposition of amyloid-β, including amyloid-β plaques, in a human neural stem-cell-derived three-dimensional (3D) culture system. More importantly, the 3D-differentiated neuronal cells expressing FAD mutations exhibited high levels of detergent-resistant, silver-positive aggregates of phosphorylated tau in the soma and neurites, as well as filamentous tau, as detected by immunoelectron microscopy. Inhibition of amyloid-β generation with β- or γ-secretase inhibitors not only decreased amyloid-β pathology, but also attenuated tauopathy. We also found that glycogen synthase kinase 3 (GSK3) regulated amyloid-β-mediated tau phosphorylation. We have successfully recapitulated amyloid-β and tau pathology in a single 3D human neural cell culture system. Our unique strategy for recapitulating Alzheimer's disease pathology in a 3D neural cell culture model should also serve to facilitate the development of more precise human neural cell models of other neurodegenerative disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Beading or blebbing in neurites is a marker of dystrophic neurites in the AD brain (3, 42, 43).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In AD, tau protein becomes hyperphosphorylated, resulting in tau dissociating from microtubules and forming insoluble tau aggregates in the neurites and cell bodies (3, 37).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In iPSC-derived neurons from both FAD- and SAD-patients, pTau aberrantly accumulates at early time points (Choi et al., 2014, Israel et al., 2012, Moore et al., 2015, Muratore et al., 2014, Ochalek et al., 2017, Shi et al., 2012).”
From Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons (2019) · cites this paper as Choi et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Modeling these pathological hallmarks has largely relied on transgenic cellular and animal models harboring genetic mutations linked to ADAD (3–5).”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“As for human neurons, previous studies focused on overexpressing mutant APP and Presenilin in REN stem cells grown in a 3D culture (3), which differs from patient-specific LOAD model that relies on the endogenous recapitulation of AD-associated phenotypes as provided in this study.”
From Modeling late-onset Alzheimer’s disease neuropathology via direct neuronal reprogramming (2024) · cites this paper as [3]
In the citing paper
“one study revealed that familial AD (FAD) mutations in β-amyloid precursor protein and presenilin 1 induced robust extracellular deposition of amyloid-β in a human neural stem-cell-derived 3D culture system85.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [85]
In the citing paper
“the 3D-differentiated neuronal cells expressing FAD mutations exhibited aggregates of phosphorylated tau as well as filamentous tau.”
From The use of brain organoids to investigate neural development and disease (2017) · cites this paper as [85]
In the citing paper
“A 3D in vitro culture system consisting of human neurons differentiated from induced pluripotent stem cells overexpressing human APP containing FAD mutations generates robust Aβ42 production and amyloid deposition. Importantly, this model also develops elevated phospho-tau levels and fibrillary tau aggregates, suggesting that elevated Aβ levels alone are sufficient to drive tau pathology in human”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Choi et al., 2014
In the citing paper
“It was recently shown that development of a 3D culture of human neural stem cells transfected with APPK670N/M671L/V717I and PS1ΔE9 in Matrigel scaffolding resulted in the extracellular aggregation of Aβ into plaques and the intracellular aggregation of tau in dystrophic neurites and the cell soma [23, 77].”
From Alzheimer's disease: experimental models and reality (2017) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Cerebral organoids model human brain development and microcephaly
Lancaster, M. A., Renner, M., Martin, C.-A., Wenzel, D., Bicknell, L. S., Hurles, M. E., Homfray, T., Penninger, J. M., Jackson, A. P., & Knoblich, J. A. (2013) · Nature · doi:10.1038/nature12517 · Cited by 5,372
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective
Tanzi, R. E., & Bertram, L. (2005) · Cell · doi:10.1016/j.cell.2005.02.008 · Cited by 1,849
Self-citationProbing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
GSK-3α regulates production of Alzheimer's disease amyloid-β peptides
Phiel, C. J., Wilson, C., Lee, V. M. ‐., & Klein, P. S. (2003) · Nature · doi:10.1038/nature01640 · Cited by 1,211
Kondo, T., Asai, M., Tsukita, K., Kutoku, Y., Ohsawa, Y., Sunada, Y., Imamura, K., Egawa, N., Yahata, N., Okita, K., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.01.009 · Cited by 741
Modeling familial Alzheimer's disease with induced pluripotent stem cells
Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr394 · Cited by 599
Cohen, R. M., Rezai-Zadeh, K. P., Weitz, T. M., Rentsendorj, A., Gate, D., Spivak, I. E., Bholat, Y., Vasilevko, V., Glabe, C. G., Breunig, J. J., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3672-12.2013 · Cited by 555
Muratore, C. R., Rice, H. C., Srikanth, P., Callahan, D. G., Shin, T., Benjamin, L. N. P., Walsh, D. M., Selkoe, D. J., & Young-Pearse, T. L. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu064 · Cited by 379
Flagged first, then by citations
Research works printed but not linked: 1
- Higuchi, M., Trojanowski, J. Q. & Lee, V. M.-Y. Tau protein and tauopathy. Neuropsychopharmacology: The Fifth Generation of Progress (eds Davis, K. L., Charney, D., Coyle, J. T. & Nemeroff, C. ) 1339–1354 (Lippincott, Williams & Wilkins, 2002)
Cited by
Sorted by citations
Items 101–200 of 998
Berman, M. H., Halper, J. P., Nichols, T. W., Jarrett, H., Lundy, A., & Huang, J. H. (2017) · Journal of Neurology and Neuroscience · doi:10.21767/2171-6625.1000176 · Cited by 168
Chen, Y.-A., Lu, C.-H., Ke, C.-C., Chiu, S.-J., Jeng, F.-S., Chang, C.-W., Yang, B.-H., & Liu, R.-S. (2021) · Biomedicines · doi:10.3390/biomedicines9060594 · Cited by 167
Zhang, Z., Freitas, B., Qian, H., Lux, J., Acab, A., Trujillo, C. A., Herai, R. H., Huu, V. A. N., Wen, J. H., Joshi-Barr, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521255113 · Cited by 164
Yamazaki, Y., Painter, M. M., Bu, G., & Kanekiyo, T. (2016) · CNS Drugs · doi:10.1007/s40263-016-0361-4 · Cited by 173
Scaffolds for 3D in vitro culture of neural lineage cells
Murphy, A. R., Laslett, A. L., O’Brien, C., & Cameron, N. R. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.02.046 · Cited by 160
Baxi, E. G., Thompson, T. G., Li, J., Kaye, J., Lim, R. G., Wu, J., Ramamoorthy, D., Lima, L. D. A., Vaibhav, V., Matlock, A. D., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-021-01006-0 · Cited by 166
Neuronal Gene Targets of NF-κB and Their Dysregulation in Alzheimer's Disease
Snow, W. M., & Albensi, B. C. (2016) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2016.00118 · Cited by 161
Rabinovici, G. D., Carrillo, M. C., Forman, M. S., DeSanti, S., Miller, D. S., Kozauer, N., Petersen, R. C., RANDOLPH, C. C., Knopman, D. S., Smith, E. E., et al. (2016) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2016.09.002 · Cited by 160
In Vitro Microfluidic Models for Neurodegenerative Disorders
Osaki, T., Shin, Y., Sivathanu, V., Campisi, M., & Kamm, R. D. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700489 · Cited by 155
Kwak, S. S., Washicosky, K. J., Brand, E., von Maydell, D., Aronson, J., Kim, S., Capen, D. E., Cetinbas, M., Sadreyev, R., Ning, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15120-3 · Cited by 151
Self-citationSposito, T., Preza, E., Mahoney, C. J., Setó-Salvia, N., Ryan, N. S., Morris, H. R., Arber, C., Devine, M. J., Houlden, H., Warner, T. T., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv246 · Cited by 148
Recent advances in optical imaging through deep tissue: imaging probes and techniques
Yoon, S., Cheon, S. Y., Park, S., Lee, D., Lee, Y., Han, S., Kim, M., & Koo, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00303-4 · Cited by 146
Bolognin, S., Fossépré, M., Qing, X., Jarazo, J., Ščančar, J., Moreno, E. L., Nickels, S., Wasner, K., Ouzren-Zarhloul, N., Walter, J., et al. (2018) · Advanced Science · doi:10.1002/advs.201800927 · Cited by 151
Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders
Vissers, C. B., Ming, G., & Song, H. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.02.007 · Cited by 146
Stem cell models of Alzheimer’s disease: progress and challenges
Arber, C., Lovejoy, C., & Wray, S. (2017) · Alzheimer's Research & Therapy · doi:10.1186/s13195-017-0268-4 · Cited by 143
Papadimitriou, C., Celikkaya, H., Cosacak, M. I., Mashkaryan, V., Bray, L., Bhattarai, P., Brandt, K., Hollak, H., Chen, X., He, S., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.06.005 · Cited by 143
Tabet, R., Schaeffer, L., Freyermuth, F., Jambeau, M., Workman, M. J., Lee, C.-Z., Lin, C.-C., Jiang, J., Jansen‐West, K. R., Hamdan, H. A., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02643-5 · Cited by 144
Best Practices for Translational Disease Modeling Using Human iPSC-Derived Neurons
Engle, S. J., Blaha, L. C., & Kleiman, R. J. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.033 · Cited by 148
Overview of Transgenic Mouse Models for Alzheimer's Disease
Myers, A., & McGonigle, P. (2019) · Current Protocols in Neuroscience · doi:10.1002/cpns.81 · Cited by 148
Stem Cells, Genome Editing, and the Path to Translational Medicine
Soldner, F., & Jaenisch, R. (2018) · Cell · doi:10.1016/j.cell.2018.09.010 · Cited by 144
Haziza, S., Mohan, N., Loe-Mie, Y., Lepagnol-Bestel, A.-M., Massou, S., Adam, M., Xuan, L. L., Viard, J., Plançon, C., Daudin, R., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.260 · Cited by 145
DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE
Cummings, J., & Fox, N. (2017) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2017.12 · Cited by 139
3D bioprinting of human neural tissues with functional connectivity
Yan, Y., Li, X., Gao, Y., Mathivanan, S., Kong, L., Tao, Y., Dong, Y. W., Li, X., Bhattacharyya, A., Zhao, X., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2023.12.009 · Cited by 144
Yılmaz, A., Geddes, T., Han, B., Bahado-Singh, R. O., Wilson, G. D., Imam, K., Maddens, M. E., & Graham, S. F. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161226 · Cited by 142
Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease
Lloret, A., Fuchsberger, T., Giraldo, E., & Viña, J. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.02.028 · Cited by 135
Three-Dimensional Neural Spheroid Culture: An In Vitro Model for Cortical Studies
Dingle, Y. L., Boutin, M. E., Chirila, A. M., Livi, L. L., Labriola, N. R., Jakubek, L. M., Morgan, J. R., Darling, E. M., Kauer, J. A., & Hoffman–Kim, D. (2015) · Tissue Engineering Part C Methods · doi:10.1089/ten.tec.2015.0135 · Cited by 138
3D culture models of Alzheimer’s disease: a road map to a “cure-in-a-dish”
Choi, S. H., Kim, Y. H., Quinti, L., Tanzi, R. E., & Kim, D. Y. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0139-7 · Cited by 132
Self-citationWang, H., Ran, H.-F., Yin, Y., Xu, X., Jiang, B.-X., Yu, S.-Q., Chen, Y., Ren, H., Feng, S., Zhang, J., et al. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00803-4 · Cited by 131
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
Self-citationAlzheimer’s Retinopathy: Seeing Disease in the Eyes
Mirzaei, N., Shi, H., Oviatt, M., Doustar, J., Rentsendorj, A., Fuchs, D.-T. S., Sheyn, J., Black, K. L., Koronyo, Y., & Koronyo‐Hamaoui, M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00921 · Cited by 136
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 136
Recent progress in translational engineered in vitro models of the central nervous system
Nikolakopoulou, P., Rauti, R., Voulgaris, D., Shlomy, I., Maoz, B. M., & Herland, A. (2020) · Brain · doi:10.1093/brain/awaa268 · Cited by 133
Cosacak, M. I., Bhattarai, P., Reinhardt, S., Petzold, A., Dahl, A., Zhang, Y., & Kizil, C. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.090 · Cited by 116
Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells
Mungenast, A. E., Siegert, S., & Tsai, L. (2015) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2015.11.010 · Cited by 136
Sidorov, V. Y., Samson, P. C., Sidorova, T. N., Davidson, J. M., Lim, C. C., & Wikswo, J. P. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.11.009 · Cited by 127
Wang, H., Yang, F., Zhang, S., Xin, R., & Sun, Y. (2021) · npj Parkinson s Disease · doi:10.1038/s41531-021-00213-7 · Cited by 135
Kim, E., Kim, H., Jedrychowski, M. P., Bakiasi, G., Park, J., Kruskop, J. M., Choi, Y., Kwak, S. S., Quinti, L., Kim, D. Y., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.08.012 · Cited by 141
Self-citationThree-dimensional modeling of human neurodegeneration: brain organoids coming of age
Grenier, K., Kao, J., & Diamandis, P. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0500-7 · Cited by 131
Chandrasekaran, A., Avci, H. X., Ochałek, A., Rösingh, L., Molnár, K., László, L., Bellák, T., Téglási, A., Pesti, K., Mike, A., et al. (2017) · Stem Cell Research · doi:10.1016/j.scr.2017.10.010 · Cited by 123
Structure-based inhibitors of amyloid beta core suggest a common interface with tau
Griner, S. L., Seidler, P., Bowler, J., Murray, K. A., Yang, T. P., Sahay, S., Sawaya, M. R., Cascio, D., Rodriguez, J. A., Philipp, S., et al. (2019) · eLife · doi:10.7554/elife.46924 · Cited by 121
Leveraging preclinical models for the development of Alzheimer disease therapeutics
Scearce-Levie, K. A., Sanchez, P. E., & Lewcock, J. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0065-9 · Cited by 121
Neuropathogenesis-on-chips for neurodegenerative diseases
Amartumur, S., Nguyen, H. M., Huynh, T., Kim, T. S., Woo, R., Oh, E., Kim, K. K., Lee, L. P., & Heo, C. (2024) · Nature Communications · doi:10.1038/s41467-024-46554-8 · Cited by 131
Logan, S., Arzua, T., Canfield, S. G., Seminary, E. R., Sison, S. L., Ebert, A. D., & Bai, X. (2019) · Comprehensive physiology · doi:10.1002/cphy.c180025 · Cited by 143
Dendritic Spines in Alzheimer’s Disease: How the Actin Cytoskeleton Contributes to Synaptic Failure
Pelucchi, S., Stringhi, R., & Marcello, E. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030908 · Cited by 117
Tissue Engineering 3D Neurovascular Units: A Biomaterials and Bioprinting Perspective
Potjewyd, G., Moxon, S. R., Wang, T., Domingos, M. A. N., & Hooper, N. M. (2018) · Trends in biotechnology · doi:10.1016/j.tibtech.2018.01.003 · Cited by 122
Alzheimer's Disease Mechanisms and Emerging Roads to Novel Therapeutics
Sala Frigerio, C., & De Strooper, B. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014015 · Cited by 116
Wesén, E. V., Jeffries, G. D. M., Dzebo, M. M., & Esbjörner, E. K. (2017) · Scientific Reports · doi:10.1038/s41598-017-02227-9 · Cited by 115
The neuritic plaque facilitates pathological conversion of tau in an Alzheimer’s disease mouse model
Li, T., Braunstein, K. E., Zhang, J., Lau, A., Sibener, L., Deeble, C., & Wong, P. C. (2016) · Nature Communications · doi:10.1038/ncomms12082 · Cited by 114
Human Neurospheroid Arrays for In Vitro Studies of Alzheimer’s Disease
Jorfi, M., D’Avanzo, C., Tanzi, R. E., Kim, D. Y., & Irimia, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-20436-8 · Cited by 112
Self-citationAlzheimer's in 3D culture: Challenges and perspectives
D'Avanzo, C., Aronson, J., Kim, Y. H., Choi, S. H., Tanzi, R. E., & Kim, D. Y. (2015) · BioEssays · doi:10.1002/bies.201500063 · Cited by 111
Self-citationOn human pluripotent stem cell control: The rise of 3D bioengineering and mechanobiology
Shao, Y., Sang, J., & Fu, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.078 · Cited by 117
Modeling and Targeting Alzheimer’s Disease With Organoids
Papaspyropoulos, A., Tsolaki, M., Foroglou, N., & Pantazaki, Α. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00396 · Cited by 107
Fabrication techniques of biomimetic scaffolds in three‐dimensional cell culture: A review
Badekila, A. K., Kini, S., & Jaiswal, A. K. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29935 · Cited by 108
Bassil, R., Shields, K., Granger, K., Zein, I., Ng, S., & Chih, B. (2021) · Nature Communications · doi:10.1038/s41467-021-25344-6 · Cited by 106
Chiarini, A., Armato, U., Gardenal, E., Gui, L., & Prà, I. D. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00217 · Cited by 109
The Exceptional Vulnerability of Humans to Alzheimer’s Disease
Walker, L. C., & Jucker, M. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.04.001 · Cited by 108
Advances in microfluidic in vitro systems for neurological disease modeling
Holloway, P. M., Willaime‐Morawek, S., Siow, R. C. M., Barber, M., Owens, R. M., Sharma, A. D., Rowan, W. C., Hill, E. J., & Zagnoni, M. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24794 · Cited by 101
Caccamo, A., Branca, C., Talboom, J. S., Shaw, D. M., Turner, D., Ma, L., Messina, A. A., Huang, Z., Wu, J., & Oddo, S. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.2781-15.2015 · Cited by 105
Three‐Dimensional Models of the Human Brain Development and Diseases
Jorfi, M., D’Avanzo, C., Kim, D. Y., & Irimia, D. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700723 · Cited by 106
Self-citationLi, H., Liu, C.-C., Zheng, H., & Huang, T. Y. (2018) · Translational Neurodegeneration · doi:10.1186/s40035-018-0139-3 · Cited by 103
Barák, M., Fedorová, V., Pospíšilová, V., Raška, J., Vochyánová, S., Sedmík, J., Hříbková, H., Klímová, H., Váňová, T., & Bohačiaková, D. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10254-3 · Cited by 102
The cellular model for Alzheimer's disease research: PC12 cells
Xie, D., Deng, T., Zhai, Z., Sun, T., & Xu, Y. D. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1016559 · Cited by 107
Effects of 3D culturing conditions on the transcriptomic profile of stem-cell-derived neurons
Tekin, H., Simmons, S., Cummings, B. B., Gao, L. A., Adiconis, X., Hession, C. C., Ghoshal, A., Dionne, D. A., Choudhury, S., Yesilyurt, V., et al. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0219-9 · Cited by 97
Applications of brain organoids in neurodevelopment and neurological diseases
Sun, N., Meng, X., Liu, Y., Song, D., Jiang, C., & Cai, J. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00728-4 · Cited by 103
Bio-inspired 3D microenvironments: a new dimension in tissue engineering
Magin, C. M., Alge, D. L., & Anseth, K. S. (2016) · Biomedical Materials · doi:10.1088/1748-6041/11/2/022001 · Cited by 100
Zhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A. M., Shen, X., Ran, C., Elmaleh, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19641-2 · Cited by 99
Self-citationEstrogen receptor β in Alzheimer’s disease: From mechanisms to therapeutics
Zhao, L., Woody, S. K., & Chhibber, A. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.08.001 · Cited by 103
In vitro bioengineered model of cortical brain tissue
Chwalek, K., Tang‐Schomer, M. D., Omenetto, F. G., & Kaplan, D. L. (2015) · Nature Protocols · doi:10.1038/nprot.2015.091 · Cited by 97
Accelerating stem cell trials for Alzheimer's disease
Hunsberger, J. G., Rao, M. S., Kurtzberg, J., Bulte, J. W. M., Atala, A., LaFerla, F. M., Greely, H. T., Sawa, A., Gandy, S., Schneider, L. S. S., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00332-4 · Cited by 98
Present and future of modeling human brain development in 3D organoids
Quadrato, G., & Arlotta, P. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.11.010 · Cited by 100
Vitamin D and Alzheimer’s Disease: Neurocognition to Therapeutics
Banerjee, A., Khemka, V. K., Ganguly, A., Roy, D., Ganguly, U., & Chakrabarti, S. (2015) · International Journal of Alzheimer s Disease · doi:10.1155/2015/192747 · Cited by 101
Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies
Crespi, G. A. N., Hermans, S. J., Parker, M. W., & Miles, L. A. (2015) · Scientific Reports · doi:10.1038/srep09649 · Cited by 96
Alzheimer's disease: The amyloid hypothesis on trial
Harrison, J. R., & Owen, M. J. (2016) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.115.167569 · Cited by 98
Harnessing endophenotypes and network medicine for Alzheimer's drug repurposing
Fang, J., Pieper, A. A., Nussinov, R., Lee, G., Bekris, L. M., Leverenz, J. B., Cummings, J. L., & Cheng, F. (2020) · Medicinal Research Reviews · doi:10.1002/med.21709 · Cited by 96
Pavoni, S., Jarray, R., Nassor, F., Guyot, A.-C., Cottin, S., Rontard, J., Mikol, J., Mabondzo, A., Deslys, J.-P., & Yates, F. (2018) · PLOS ONE · doi:10.1371/journal.pone.0209150 · Cited by 97
Wang, Y., Veremeyko, T., Wong, A. H.-K., El Fatimy, R., Wei, Z., Cai, W., & Krichevsky, A. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.12.015 · Cited by 87
Vojtechova, I., Machacek, T., Kristofikova, Z., Stuchlik, A., & Petrasek, T. (2022) · PLOS Pathogens · doi:10.1371/journal.ppat.1010929 · Cited by 92
Creation of a library of induced pluripotent stem cells from Parkinsonian patients
Holmqvist, S., Lehtonen, Š., Chumarina, M., Puttonen, K. A., Azevedo, C., Lebedeva, O. S., Ruponen, M., Oksanen, M., Djelloul, M., Collin, A., et al. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2016.9 · Cited by 91
Opportunities for organoids as new models of aging
Hu, J. L., Todhunter, M. E., LaBarge, M. A., & Gartner, Z. J. (2017) · The Journal of Cell Biology · doi:10.1083/jcb.201709054 · Cited by 92
He, Z., An, S., Chen, J., Zhang, S., Tan, C., Yu, J., Ye, H., Wu, Y., Yuan, J. X., Wu, J., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2007773117 · Cited by 87
The Application of Brain Organoids: From Neuronal Development to Neurological Diseases
Shou, Y., Liang, F., Xu, S., & Li, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.579659 · Cited by 87
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöhr, J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 92
Innovations in 3D Tissue Models of Human Brain Physiology and Diseases
Lovett, M. L., Nieland, T. J. F., Dingle, Y. L., & Kaplan, D. L. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201909146 · Cited by 87
Cell models for Alzheimer’s and Parkinson’s disease: At the interface of biology and drug discovery
Cetin, S., Knez, D., Gobec, S., Kos, J., & Pišlar, A. H. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112924 · Cited by 92
Bukhari, H., Glotzbach, A., Kolbe, K., Leonhardt, G., Loosse, C., & Müller, T. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.05.005 · Cited by 88
Using Human iPSC-Derived Neurons to Model TAU Aggregation
Verheyen, A., Diels, A., Dijkmans, J., Oyelami, T., Meneghello, G., Mertens, L., Versweyveld, S., Borgers, M., Buist, A., Peeters, P., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0146127 · Cited by 86
Synaptic dysfunction in early phases of Alzheimer's Disease
Pelucchi, S., Gardoni, F., Luca, M. D., & Marcello, E. E. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00022-9 · Cited by 95
Snow, A. D., Cummings, J. A., & Lake, T. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.710683 · Cited by 84
Cairns, D. M., Chwalek, K., Moore, Y. E., Kelley, M. R., Abbott, R. D., Moss, S. J., & Kaplan, D. L. (2016) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.07.017 · Cited by 84
Recent Progress in Alzheimer’s Disease Research, Part 1: Pathology
Hane, F. T., Lee, B. Y., & Leonenko, Z. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160882 · Cited by 92
Tan, H. Y., Cho, H., & Lee, L. P. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00643-3 · Cited by 87
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 85
Yang, J., Li, S., He, X., Cheng, C., & Le, W. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0106-3 · Cited by 86
Human pluripotent stem cell–derived models and drug screening in CNS precision medicine
Silva, M. C., & Haggarty, S. J. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14012 · Cited by 88
Challenges and Opportunities in Central Nervous System Drug Discovery
Danon, J. J., Reekie, T. A., & Kassiou, M. (2019) · Trends in Chemistry · doi:10.1016/j.trechm.2019.04.009 · Cited by 86
Midbrain Organoids: A New Tool to Investigate Parkinson’s Disease
Smits, L. M., & Schwamborn, J. C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00359 · Cited by 87
Haston, K. M., & Finkbeiner, S. M. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103548 · Cited by 84
Kobro‐Flatmoen, A., Nagelhus, A., & Witter, M. P. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.012 · Cited by 78
Neurophysiological Changes Induced by Chronic Toxoplasma gondii Infection
Tedford, E., & McConkey, G. A. (2017) · Pathogens · doi:10.3390/pathogens6020019 · Cited by 83
Metadata
- Authors
- Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., Klee, J. B., Zhang, C., Wainger, B. J., Peitz, M., Kovacs, D. M., Woolf, C. J., Wagner, S. L., Tanzi, R. E., & Kim, D. Y.
- Affiliations
- Harvard University (US)
- University of Bonn (DE)
- Boston Children's Hospital (US)
- Whitehead Institute for Biomedical Research (US)
- University of California San Diego (US)
- Corresponding author
- Tanzi, Rudolph E.
- Kim, Doo Yeon
- ORCID
- Venue
- Nature
- Published
- 2014-10-12
- Volume
- 515
- Issue
- 7526
- Pages
- 274-278
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4366007
- OpenAlex
- W2126231259
- Cited by
- 1,195
- References
- 30
- Citations by year
- 2026: 67 · 2025: 75 · 2024: 95 · 2023: 88 · 2022: 112 · 2021: 111 · 2020: 141 · 2019: 109 · 2018: 109 · 2017: 87 · 2016: 97 · 2015: 87 · 2014: 14
- FWCI
- 63.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Massachusetts General Hospital
- Cure Alzheimer's Fund
- University of Edinburgh
- National Institute on Aging (5P01 AG15379, P01AG015379, R21AG031483, RF1AG048080, P50AG005134, R01AG014713, P01AG004953, P30AG062421)
- National Institute of Mental Health (R37MH060009)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK057521, P30DK043351)
- National Institute of Neurological Disorders and Stroke (P30NS045776, R01NS045860)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (P30HD018655)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, familial Alzheimer's disease, amyloid plaques, tauopathy, neurofibrillary tangles, amyloid hypothesis, presenilin 1 mutations, human neural stem cells, 3D cell culture, human neurons, beta-secretase inhibition, gamma-secretase inhibition, tau phosphorylation, drug screening model
- MeSH terms
- Alzheimer Disease, Cell Differentiation, Drug Evaluation, Preclinical, Extracellular Space, Humans, Microtubule-Associated Proteins, Models, Biological, Phosphorylation, Reproducibility of Results, Amyloid beta-Peptides, Neurites, tau Proteins, Cell Culture Techniques, Glycogen Synthase Kinase 3, Presenilin-1, Neural Stem Cells, Protein Aggregation, Pathological
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
